|
|
||||||||


Departments of
* Internal Medicine and
Cell and Developmental Biology, University of Michigan, and
Ann Arbor Veterans Affairs, Ann Arbor, MI 48109
Individuals with systemic lupus erythematosus show evidence of a significant increase in monocyte apoptosis. This process is mediated, at least in part, by an autoreactive T cell subset that kills autologous monocytes in the absence of nominal Ag. We have investigated the apoptotic pathways involved in this T cell-mediated process. Expression of the apoptotic ligands TRAIL, TNF-like weak inducer of apoptosis (TWEAK), and Fas ligand on lupus T cells was determined, and the role of these molecules in the monocyte apoptotic response was examined. We report that these apoptotic ligands mediate the autologous monocyte death induced by lupus T cells and that this cytotoxicity is associated with increased expression of these molecules on activated T cells, rather than with an increased susceptibility of lupus monocytes to apoptosis induced by these ligands. These results define novel mechanisms that contribute to increased monocyte apoptosis characterizing patients with lupus. We propose that this mechanism could provide a source of potentially antigenic material for the autoimmune response and interfere with normal clearing mechanisms.
This article has been cited by other articles:
![]() |
M. Kumar, D. Y. Makonchuk, H. Li, A. Mittal, and A. Kumar TNF-Like Weak Inducer of Apoptosis (TWEAK) Activates Proinflammatory Signaling Pathways and Gene Expression through the Activation of TGF-{beta}-Activated Kinase 1 J. Immunol., February 15, 2009; 182(4): 2439 - 2448. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Desplat-Jego, L. Feuillet, R. Creidy, I. Malikova, R. Rance, M. Khrestchatisky, K. Hahm, L. C. Burkly, J. Pelletier, and J. Boucraut TWEAK is expressed at the cell surface of monocytes during multiple sclerosis J. Leukoc. Biol., January 1, 2009; 85(1): 132 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Dai, C Hu, Y Huang, H. Huang, J Liu, and T Lv A proteomic study of peripheral blood mononuclear cells in systemic lupus erythematosus Lupus, September 1, 2008; 17(9): 799 - 804. [Abstract] [PDF] |
||||
![]() |
T. S. Zheng and L. C. Burkly No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies J. Leukoc. Biol., August 1, 2008; 84(2): 338 - 347. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Sanz, P. Justo, M. D. Sanchez-Nino, L. M. Blanco-Colio, J. A. Winkles, M. Kreztler, A. Jakubowski, J. Blanco, J. Egido, M. Ruiz-Ortega, et al. The Cytokine TWEAK Modulates Renal Tubulointerstitial Inflammation J. Am. Soc. Nephrol., April 1, 2008; 19(4): 695 - 703. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhao, L. C. Burkly, S. Campbell, N. Schwartz, A. Molano, A. Choudhury, R. A. Eisenberg, J. S. Michaelson, and C. Putterman TWEAK/Fn14 Interactions Are Instrumental in the Pathogenesis of Nephritis in the Chronic Graft-versus-Host Model of Systemic Lupus erythematosus J. Immunol., December 1, 2007; 179(11): 7949 - 7958. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Fionda, F. Nappi, M. Piccoli, L. Frati, A. Santoni, and M. Cippitelli Inhibition of Trail Gene Expression by Cyclopentenonic Prostaglandin 15-Deoxy-{Delta}12,14-Prostaglandin J2 in T Lymphocytes Mol. Pharmacol., November 1, 2007; 72(5): 1246 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Denny, S. Thacker, H. Mehta, E. C. Somers, T. Dodick, F. J. Barrat, W. J. McCune, and M. J. Kaplan Interferon-{alpha} promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis Blood, October 15, 2007; 110(8): 2907 - 2915. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Castellino, F. Corallini, F. Trotta, and P. Secchiero Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies Lupus, July 1, 2007; 16(7): 479 - 482. [Abstract] [PDF] |
||||
![]() |
L. C. Bover, M. Cardo-Vila, A. Kuniyasu, J. Sun, R. Rangel, M. Takeya, B. B. Aggarwal, W. Arap, and R. Pasqualini A Previously Unrecognized Protein-Protein Interaction between TWEAK and CD163: Potential Biological Implications J. Immunol., June 15, 2007; 178(12): 8183 - 8194. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kawasaki, N. Tsuchiya, J. Ohashi, Y. Murakami, T. Fukazawa, M. Kusaoi, S. Morimoto, K. Matsuta, H. Hashimoto, Y. Takasaki, et al. Role of APRIL (TNFSF13) polymorphisms in the susceptibility to systemic lupus erythematosus in Japanese Rheumatology, May 1, 2007; 46(5): 776 - 782. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Rus, V. Nguyen, R. Puliaev, I. Puliaeva, V. Zernetkina, I. Luzina, J. C. Papadimitriou, and C. S. Via T Cell TRAIL Promotes Murine Lupus by Sustaining Effector CD4 Th Cell Numbers and by Inhibiting CD8 CTL Activity J. Immunol., March 15, 2007; 178(6): 3962 - 3972. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ding, H. Mehta, W. J. McCune, and M. J. Kaplan Aberrant Phenotype and Function of Myeloid Dendritic Cells in Systemic Lupus Erythematosus J. Immunol., November 1, 2006; 177(9): 5878 - 5889. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Munoz-Garcia, J. L. Martin-Ventura, E. Martinez, S. Sanchez, G. Hernandez, L. Ortega, A. Ortiz, J. Egido, and L. M. Blanco-Colio Fn14 Is Upregulated in Cytokine-Stimulated Vascular Smooth Muscle Cells and Is Expressed in Human Carotid Atherosclerotic Plaques: Modulation by Atorvastatin Stroke, August 1, 2006; 37(8): 2044 - 2053. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Denny, P. Chandaroy, P. D. Killen, R. Caricchio, E. E. Lewis, B. C. Richardson, K.-D. Lee, J. Gavalchin, and M. J. Kaplan Accelerated Macrophage Apoptosis Induces Autoantibody Formation and Organ Damage in Systemic Lupus Erythematosus J. Immunol., February 15, 2006; 176(4): 2095 - 2104. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Arbour, E Rastikerdar, E McCrea, Y Lapierre, J Dorr, A Bar-Or, and J P Antel Upregulation of TRAIL expression on human T lymphocytes by interferon b and glatiramer acetate Multiple Sclerosis, December 1, 2005; 11(6): 652 - 657. [Abstract] [PDF] |
||||
![]() |
M N Lub-de Hooge, E G E de Vries, S de Jong, and M Bijl Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus Ann Rheum Dis, June 1, 2005; 64(6): 854 - 858. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Matsuyama, M. Yamamoto, I. Higashimoto, K.-i. Oonakahara, M. Watanabe, K. Machida, T. Yoshimura, N. Eiraku, M. Kawabata, M. Osame, et al. TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus Blood, July 1, 2004; 104(1): 184 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Kaplan, Q. Lu, A. Wu, J. Attwood, and B. Richardson Demethylation of Promoter Regulatory Elements Contributes to Perforin Overexpression in CD4+ Lupus T Cells J. Immunol., March 15, 2004; 172(6): 3652 - 3661. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Polek, M. Talpaz, B. G. Darnay, and T. Spivak-Kroizman TWEAK Mediates Signal Transduction and Differentiation of RAW264.7 Cells in the Absence of Fn14/TweakR: EVIDENCE FOR A SECOND TWEAK RECEPTOR J. Biol. Chem., August 22, 2003; 278(34): 32317 - 32323. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Kemp, B. D. Elzey, and T. S. Griffith Plasmacytoid Dendritic Cell-Derived IFN-{alpha} Induces TNF-Related Apoptosis-Inducing Ligand/Apo-2L-Mediated Antitumor Activity by Human Monocytes Following CpG Oligodeoxynucleotide Stimulation J. Immunol., July 1, 2003; 171(1): 212 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Donohue, C. M. Richards, S. A.N. Brown, H. N. Hanscom, J. Buschman, S. Thangada, T. Hla, M. S. Williams, and J. A. Winkles TWEAK Is an Endothelial Cell Growth and Chemotactic Factor That Also Potentiates FGF-2 and VEGF-A Mitogenic Activity Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 594 - 600. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |